Immunoadsorption as a method of antibody donation during the COVID-19 pandemic.

IF 1.8 4区医学 Q3 HEMATOLOGY Vox Sanguinis Pub Date : 2024-08-01 Epub Date: 2024-05-13 DOI:10.1111/vox.13647

Jannik Rothenburg, Silke Rink-Baron, Lisa Müller, Philipp Niklas Ostermann, Johannes C Fischer, Derik Hermsen, Johannes Stegbauer, Anja Moldenhauer

{"title":"Immunoadsorption as a method of antibody donation during the COVID-19 pandemic.","authors":"Jannik Rothenburg, Silke Rink-Baron, Lisa Müller, Philipp Niklas Ostermann, Johannes C Fischer, Derik Hermsen, Johannes Stegbauer, Anja Moldenhauer","doi":"10.1111/vox.13647","DOIUrl":null,"url":null,"abstract":"Background and objectives: Initial therapeutic efforts to treat severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) included the use of plasma from convalescent donors containing anti-SARS-CoV-2 antibodies. High-neutralizing antibody titres are required for therapeutic efficacy. This study aims to show that immunoadsorption followed by tangential flow filtration can be used to obtain antibody concentrates with high-neutralizing capacities.Materials and methods: Eligible donors (n = 10, five males and three females) underwent immunoadsorption using adsorber columns specific for human antibodies. Glycine-washed out eluates of 1.5 L volume were further concentrated by tangential flow filtration using 30 kDa ultrafiltration membranes. The same membranes were applied for diafiltrations to exchange residual glycine for 0.9% normal saline.Results: Antibody concentrates were obtained within 8 h from the start of donation and had 4.58 ± 1.95, 3.28 ± 1.28 and 2.02 ± 0.92 times higher total IgG, IgA and IgM concentrations, 3.29 ± 1.62 and 3.74 ± 0.6 times higher SARS-CoV-2 N and S antibody concentrations and 3.85 ± 1.71 times higher SARS-CoV-2 S-specific IgG concentrations compared to the donors' peripheral blood. The specific SARS-CoV-2 virus neutralization capacities increased in all but one concentrate. All antibody concentrates (50-70 mL final volume) passed microbiological tests, were free of hazardous glycine levels and could be stored at -80°C and 4°C for 1 year with 20 ± 3% antibody loss.Conclusion: Immunoadsorption followed by tangential flow filtration is a feasible procedure to collect IgG, IgA and IgM as well as SARS-CoV-2 N- and S-specific antibody concentrates of low volume, free of albumin and coagulation factors. Whether these concentrates can be used as passive immunisation in infected patients remains to be elucidated.","PeriodicalId":23631,"journal":{"name":"Vox Sanguinis","volume":" ","pages":"792-800"},"PeriodicalIF":1.8000,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Vox Sanguinis","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/vox.13647","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/5/13 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background and objectives: Initial therapeutic efforts to treat severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) included the use of plasma from convalescent donors containing anti-SARS-CoV-2 antibodies. High-neutralizing antibody titres are required for therapeutic efficacy. This study aims to show that immunoadsorption followed by tangential flow filtration can be used to obtain antibody concentrates with high-neutralizing capacities.

Materials and methods: Eligible donors (n = 10, five males and three females) underwent immunoadsorption using adsorber columns specific for human antibodies. Glycine-washed out eluates of 1.5 L volume were further concentrated by tangential flow filtration using 30 kDa ultrafiltration membranes. The same membranes were applied for diafiltrations to exchange residual glycine for 0.9% normal saline.

Results: Antibody concentrates were obtained within 8 h from the start of donation and had 4.58 ± 1.95, 3.28 ± 1.28 and 2.02 ± 0.92 times higher total IgG, IgA and IgM concentrations, 3.29 ± 1.62 and 3.74 ± 0.6 times higher SARS-CoV-2 N and S antibody concentrations and 3.85 ± 1.71 times higher SARS-CoV-2 S-specific IgG concentrations compared to the donors' peripheral blood. The specific SARS-CoV-2 virus neutralization capacities increased in all but one concentrate. All antibody concentrates (50-70 mL final volume) passed microbiological tests, were free of hazardous glycine levels and could be stored at -80°C and 4°C for 1 year with 20 ± 3% antibody loss.

Conclusion: Immunoadsorption followed by tangential flow filtration is a feasible procedure to collect IgG, IgA and IgM as well as SARS-CoV-2 N- and S-specific antibody concentrates of low volume, free of albumin and coagulation factors. Whether these concentrates can be used as passive immunisation in infected patients remains to be elucidated.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

在 COVID-19 大流行期间将免疫吸附作为一种抗体捐赠方法。

背景和目的：治疗严重急性呼吸系统综合征冠状病毒 2（SARS-CoV-2）的最初疗法包括使用含有抗 SARS-CoV-2 抗体的康复捐献者血浆。治疗效果需要高中和性抗体滴度。本研究旨在证明免疫吸附后切向流过滤可用于获得具有高中和作用的抗体浓缩物：符合条件的供体（n = 10，5 男 3 女）使用人类抗体特异性吸附柱进行免疫吸附。用 30 kDa 超滤膜进行切向流过滤，进一步浓缩甘氨酸洗脱液（1.5 升）。用同样的膜进行重过滤，将残留的甘氨酸换成 0.9% 的生理盐水：与捐献者外周血相比，抗体浓缩物的总 IgG、IgA 和 IgM 浓度分别为 4.58 ± 1.95、3.28 ± 1.28 和 2.02 ± 0.92 倍，SARS-CoV-2 N 和 S 抗体浓度分别为 3.29 ± 1.62 和 3.74 ± 0.6 倍，SARS-CoV-2 S 特异性 IgG 浓度为 3.85 ± 1.71 倍。除一种浓缩液外，其他所有浓缩液的 SARS-CoV-2 病毒特异性中和能力都有所提高。所有抗体浓缩液（50-70 毫升最终体积）都通过了微生物测试，不含有害的甘氨酸，可在 -80°C 和 4°C 下保存 1 年，抗体损失率为 20 ± 3%：结论：免疫吸附后切向流过滤是收集 IgG、IgA 和 IgM 以及 SARS-CoV-2 N 和 S 特异性抗体浓缩物的可行方法，浓缩物体积小，不含白蛋白和凝血因子。这些浓缩物是否可用于感染患者的被动免疫，还有待进一步阐明。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Vox Sanguinis 医学-血液学

CiteScore

4.40

自引率

11.10%

发文量

156

审稿时长

6-12 weeks

期刊介绍： Vox Sanguinis reports on important, novel developments in transfusion medicine. Original papers, reviews and international fora are published on all aspects of blood transfusion and tissue transplantation, comprising five main sections: 1) Transfusion - Transmitted Disease and its Prevention: Identification and epidemiology of infectious agents transmissible by blood; Bacterial contamination of blood components; Donor recruitment and selection methods; Pathogen inactivation. 2) Blood Component Collection and Production: Blood collection methods and devices (including apheresis); Plasma fractionation techniques and plasma derivatives; Preparation of labile blood components; Inventory management; Hematopoietic progenitor cell collection and storage; Collection and storage of tissues; Quality management and good manufacturing practice; Automation and information technology. 3) Transfusion Medicine and New Therapies: Transfusion thresholds and audits; Haemovigilance; Clinical trials regarding appropriate haemotherapy; Non-infectious adverse affects of transfusion; Therapeutic apheresis; Support of transplant patients; Gene therapy and immunotherapy. 4) Immunohaematology and Immunogenetics: Autoimmunity in haematology; Alloimmunity of blood; Pre-transfusion testing; Immunodiagnostics; Immunobiology; Complement in immunohaematology; Blood typing reagents; Genetic markers of blood cells and serum proteins: polymorphisms and function; Genetic markers and disease; Parentage testing and forensic immunohaematology. 5) Cellular Therapy: Cell-based therapies; Stem cell sources; Stem cell processing and storage; Stem cell products; Stem cell plasticity; Regenerative medicine with cells; Cellular immunotherapy; Molecular therapy; Gene therapy.